"This is a pretty clear failure. Physicians should now stop using ezetimibe or Vytorin except as a last resort." - Dr. Steven Nissen (Cleveland Clinic, OH) "Dr. Nissen's suggestion about a moratorium on ezitimibe is rather alarmist, given that this was just an imaging study, and an imaging study should not change clinical practice." - Dr. Robert Harrington (Duke Clinical Research Institute, Durham, NC) These 2 quotes pertain to the January 14th release of the ENHANCE study, a trial that evaluated the effects of ezetimibe + simvastatin (aka Vytorin ) on preventing neck artery thickness. As you can tell, the announcement by the manufacturers Merck and Schering-Plough was disappointingly negative and has generated significant controversy. Talk about timing. I just wrote my last article in early January on ezetimibe and how the liver safety of this medication when used in combination with a statin was called into question. One reaso...
Generic Name: SITAGLIPTIN/SIMVASTATIN - ORAL Pronounced: (SYE-ta-GLIP-tin/SIM-va-STAT-in) sitagliptin-simvastatin Oral Precautions
Before taking this product, tell your doctor or pharmacist
if you are allergic to sitagliptin or simvastatin; or if you have any other
allergies. This product may contain inactive ingredients, which can cause
allergic reactions or other problems. Talk to your pharmacist for more
Before using this medication, tell your doctor or
pharmacist your medical history, especially of:
disease of the pancreas (pancreatitis)
You may experience blurred vision, dizziness, or
drowsiness due to extremely low or high blood sugar levels. Do not drive, use
machinery, or do any activity that requires alertness or clear vision until you
are sure you can perform such activities safely.
Before having surgery, tell your doctor or dentist about
all the p...
The makers of Vytorin®, Merck/Schering-Plough Pharmaceuticals, recently issued a controversial press release about the Enhance Study that compared the effects of Vytorin® (a combination of simvastatin and ezetimibe, brand name Zetia®) vs. just simvastatin. No substantial difference was observed with the addition of Zetia®, perhaps even a negative effect. The news has triggered a media frenzy. The New York Times headlined the story, " Drug Has No Benefit in Trial ." "Drug doesn't slow artery clogs," declares the Washington Post . A medical marketing website declared "Vytorin study's a stinker." This has been followed by some journalists and scientists calling the entire lipid hypothesis , the notion that high cholesterol forms atherosclerotic plaque and heart disease, into doubt. "New Questions on Treating Cholesterol" ( http://www.nytimes.com/2008/01/17/business/17drug.html?ex=1358312400&en=11b68f069a83f57c&a...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.